Home › Compare › TMBR vs QYLD

TMBR vs QYLD: Dividend Comparison 2026

TMBR yields 583.77% · QYLD yields 12.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TMBR wins by $207588.14M in total portfolio value
10 years
TMBR
TMBR
● Live price
583.77%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207588.17M
Annual income
$155,267,282,426.18
Full TMBR calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
12.24%
Share price
$16.70
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$6,038.84
Full QYLD calculator →

Portfolio growth — TMBR vs QYLD

📍 TMBR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTMBRQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TMBR + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TMBR pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TMBR
Annual income on $10K today (after 15% tax)
$49,620.55/yr
After 10yr DRIP, annual income (after tax)
$131,977,190,062.25/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,040.82/yr
After 10yr DRIP, annual income (after tax)
$5,133.01/yr
At 15% tax rate, TMBR beats the other by $131,977,184,929.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TMBR + QYLD for your $10,000?

TMBR: 50%QYLD: 50%
100% QYLD50/50100% TMBR
Portfolio after 10yr
$103794.10M
Annual income
$77,633,644,232.51/yr
Blended yield
74.80%
📊

Analyst Conviction Gap

Where Wall Street is split right now

TMBR
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-39.2
Piotroski
1/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TMBR buys
0
QYLD buys
0
No recent congressional trades found for TMBR or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTMBRQYLD
Forward yield583.77% ✓12.24%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$207588.17M ✓$26.5K
Annual income after 10y$155,267,282,426.18 ✓$6,038.84
Total dividends collected$203195.85M ✓$28.5K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TMBR vs QYLD ($10,000, DRIP)

YearTMBR PortfolioTMBR Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$69,077$58,377.12$10,384$1,224.49+$58.7K → TMBR
2$450,784$376,871.29$10,900$1,388.18+$439.9K → TMBR
3$2,780,833$2,298,494.08$11,576$1,590.76+$2.77M → TMBR
4$16,227,026$13,251,534.56$12,447$1,844.20+$16.21M → TMBR
5$89,630,986$72,268,068.54$13,567$2,164.97+$89.62M → TMBR
6$468,967,935$373,062,780.07$15,003$2,576.05+$468.95M → TMBR
7$2,326,040,505$1,824,244,814.49$16,853$3,110.04+$2326.02M → TMBR
8$10,945,028,688$8,456,165,347.80$19,251$3,813.85+$10945.01M → TMBR
9$48,898,024,515$37,186,843,819.07$22,390$4,756.08+$48898.00M → TMBR
10$207,588,168,658$155,267,282,426.18$26,548$6,038.84+$207588.14M → TMBR

TMBR vs QYLD: Complete Analysis 2026

TMBR — Stock

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.

Full TMBR Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TMBR vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TMBR vs SCHDTMBR vs JEPITMBR vs OTMBR vs KOTMBR vs MAINTMBR vs XYLDTMBR vs JEPQTMBR vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.